David Wild
Reporter

Latest From David Wild
Machine Learning Company Wants to Increase Use of Adaptive Trial Design
Using machine learning, PhaseV, an Israeli startup is trying to make adaptive trial design more accessible. It is early days, but the company's approach is attracting investors and partners.
AI Driving Innovation: Insights From Exscientia CEO Andrew Hopkins
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.
Companies Find Growth Opportunities In Maturing Colorectal Cancer Blood-Based Screening Market
Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.
Rethinking Commercialization Models In The Age Of Pricing And Access Complexity
In an environment replete with pricing and patient access pressures, top biopharma companies are building commercialization models that emphasize inclusive and diverse decision-making and that integrate digital tools with a human salesforce.
BioBytes: Machine Learning Could Improve Clinical Trial Diversity
With a growing focus on clinical trial diversity, companies are looking for ways to recruit from historically marginalized communities. Machine learning may help meet these diversity goals.
Ironwood Gears Up To Compete In Competitive Gastrointestinal Markets
With the acquisition of Swiss biotech firm VectivBio in late June, Ironwood Pharmaceuticals has firmly positioned itself as a gastrointestinal-focused company.